LumiraDX Ltd., a point of care diagnostics testing company, is going public via a merger with special purpose acquisition corporation, or SPAC, CA Healthcare Acquisition Corp. , in a deal with a pro forma enterprise value of about $5 billion. London-based LumiraDX has raised $700 million in equity capital since its founding in 2014, and has raised funds from investors including Morningside Ventures, U.S. Boston Capital Corporation, The Bill & Melinda Gates Foundation, Petrichor Healthcare Capital Management, among others.